Literature DB >> 15953285

Ocular compression maneuver aborts benign cough-induced headache.

Vinod Kumar Gupta1.   

Abstract

Benign cough-induced headache is a short-lasting cranial discomfort. The therapeutic role of lumbar puncture (LP) or indomethacin in benign patients with benign cough-induced headache patients is debatable. Transient ocular compression (OC) raises intraocular pressure (IOP) and can limit the impact of cough-induced choroidal venous congestion. A self-applied maneuver that instantaneously aborts cough-induced headache is described in two patients. The effect of this maneuver supports a recent hypothesis that cough-induced headache may be due to ocular choroidal venous congestion and mechanical antidromic trigeminal nerve activation. The OC maneuver has several potential complications and its self-application in benign cough-induced headache should be regarded as an experimental procedure until more data regarding its efficacy and safety become available.

Entities:  

Mesh:

Year:  2005        PMID: 15953285     DOI: 10.1111/j.1526-4610.2005.05117_4.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  4 in total

Review 1.  Systemic hypertension, headache, and ocular hemodynamics: a new hypothesis.

Authors:  Vinod Kumar Gupta
Journal:  MedGenMed       Date:  2006-09-12

2.  Headache secondary to an unusual Valsalva manoeuvre in a migrainous patient with cacosmia.

Authors:  Ferdinando Maggioni; Claudio Baracchini; Maria Lucia Malvindi; Giorgio Zanchin
Journal:  Neurol Sci       Date:  2011-03-16       Impact factor: 3.307

3.  Life-Threatening and Non-Life-Threatening Complications Associated With Coughing: A Scoping Review.

Authors:  Richard S Irwin; Natasha Dudiki; Cynthia L French
Journal:  Chest       Date:  2020-06-19       Impact factor: 9.410

4.  Modified Valsalva test differentiates primary from secondary cough headache.

Authors:  Russell J M Lane; Paul T G Davies
Journal:  J Headache Pain       Date:  2013-03-28       Impact factor: 7.277

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.